Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:HIMS NASDAQ:RXRX NASDAQ:SDGR NASDAQ:SMMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHIMSHims & Hers Health$48.25+8.5%$50.05$13.47▼$72.98$10.05B2.1422.20 million shs44.67 million shsRXRXRecursion Pharmaceuticals$4.52-2.4%$5.40$3.79▼$12.36$2.01B0.9115.23 million shs14.71 million shsSDGRSchrodinger$18.97-1.7%$20.43$16.60▼$28.47$1.42B1.791.29 million shs970,327 shsSMMTSummit Therapeutics$23.80+1.2%$25.75$11.76▼$36.91$17.47B-1.023.01 million shs2.75 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHIMSHims & Hers Health+6.91%+0.98%-29.79%-15.75%+207.23%RXRXRecursion Pharmaceuticals-0.64%-5.32%-20.17%+1.31%-23.72%SDGRSchrodinger+0.94%-2.53%-3.50%-19.09%-6.09%SMMTSummit Therapeutics-1.34%-5.20%-19.78%+19.21%+86.67%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHIMSHims & Hers Health$48.25+8.5%$50.05$13.47▼$72.98$10.05B2.1422.20 million shs44.67 million shsRXRXRecursion Pharmaceuticals$4.52-2.4%$5.40$3.79▼$12.36$2.01B0.9115.23 million shs14.71 million shsSDGRSchrodinger$18.97-1.7%$20.43$16.60▼$28.47$1.42B1.791.29 million shs970,327 shsSMMTSummit Therapeutics$23.80+1.2%$25.75$11.76▼$36.91$17.47B-1.023.01 million shs2.75 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHIMSHims & Hers Health+6.91%+0.98%-29.79%-15.75%+207.23%RXRXRecursion Pharmaceuticals-0.64%-5.32%-20.17%+1.31%-23.72%SDGRSchrodinger+0.94%-2.53%-3.50%-19.09%-6.09%SMMTSummit Therapeutics-1.34%-5.20%-19.78%+19.21%+86.67%Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHIMSHims & Hers Health$1.48B7.39$0.38 per share126.25$2.16 per share22.34RXRXRecursion Pharmaceuticals$58.84M33.35N/AN/A$2.61 per share1.73SDGRSchrodinger$207.54M6.73N/AN/A$5.78 per share3.28SMMTSummit Therapeutics$700K25,256.90N/AN/A$0.53 per share44.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHIMSHims & Hers Health$126.04M$0.8060.3192.793.009.63%26.26%13.06%11/3/2025 (Estimated)RXRXRecursion Pharmaceuticals-$463.66M-$1.78N/AN/AN/A-1,004.91%-76.09%-54.29%11/5/2025 (Estimated)SDGRSchrodinger-$187.12M-$2.48N/AN/AN/A-76.22%-45.70%-24.81%11/11/2025 (Estimated)SMMTSummit Therapeutics-$221.32M-$1.01N/AN/AN/AN/A-208.64%-181.28%10/29/2025 (Estimated)Latest SMMT, SDGR, RXRX, and HIMS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025SMMTSummit Therapeutics-$0.10-$0.76-$0.66-$0.76N/AN/A8/6/2025Q2 2025SDGRSchrodinger-$0.83-$0.59+$0.24-$0.59$52.03 million$54.76 million8/5/2025Q2 2025RXRXRecursion Pharmaceuticals-$0.35-$0.41-$0.06-$0.41$15.38 million$19.10 million8/4/2025Q2 2025HIMSHims & Hers Health$0.18$0.17-$0.01$0.17$550.06 million$544.83 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHIMSHims & Hers HealthN/AN/AN/AN/AN/ARXRXRecursion PharmaceuticalsN/AN/AN/AN/AN/ASDGRSchrodingerN/AN/AN/AN/AN/ASMMTSummit TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHIMSHims & Hers Health1.724.984.46RXRXRecursion Pharmaceuticals0.023.583.58SDGRSchrodingerN/A3.303.30SMMTSummit TherapeuticsN/A5.135.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHIMSHims & Hers Health63.52%RXRXRecursion Pharmaceuticals89.06%SDGRSchrodinger79.05%SMMTSummit Therapeutics4.61%Insider OwnershipCompanyInsider OwnershipHIMSHims & Hers Health13.71%RXRXRecursion Pharmaceuticals8.43%SDGRSchrodinger21.00%SMMTSummit Therapeutics84.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHIMSHims & Hers Health1,637226.02 million195.03 millionOptionableRXRXRecursion Pharmaceuticals400434.15 million397.55 millionOptionableSDGRSchrodinger79073.61 million58.15 millionOptionableSMMTSummit Therapeutics110742.85 million112.17 millionOptionableSMMT, SDGR, RXRX, and HIMS HeadlinesRecent News About These CompaniesSummit Therapeutics (NASDAQ:SMMT) Given Buy Rating at HC WainwrightSeptember 4 at 8:09 AM | marketbeat.comNorthern Trust Corp Has $16.27 Million Stake in Summit Therapeutics PLC $SMMTSeptember 4 at 3:34 AM | marketbeat.comHC Wainwright Reaffirms Buy Rating for Summit Therapeutics (NASDAQ:SMMT)September 4 at 3:11 AM | americanbankingnews.comSummit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025September 3 at 10:25 AM | theglobeandmail.comH.C. Wainwright Lifts PT on Summit Therapeutics (SMMT) to $50 From $44August 31, 2025 | uk.finance.yahoo.com3 No-Brainer Stocks to Buy Right NowAugust 31, 2025 | fool.comSiren L.L.C. Invests $13.41 Million in Summit Therapeutics PLC $SMMTAugust 31, 2025 | marketbeat.comHC Wainwright Has Positive Estimate for SMMT FY2026 EarningsAugust 31, 2025 | marketbeat.comRafferty Asset Management LLC Sells 81,950 Shares of Summit Therapeutics PLC $SMMTAugust 31, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for SMMT FY2026 Earnings?August 31, 2025 | americanbankingnews.comSummit Therapeutics PLC $SMMT Shares Purchased by Tema Etfs LLCAugust 30, 2025 | marketbeat.comNuveen LLC Makes New $4.55 Million Investment in Summit Therapeutics PLC $SMMTAugust 29, 2025 | marketbeat.comSummit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says AnalystAugust 27, 2025 | benzinga.comSummit Therapeutics price target raised to $50 from $44 at H.C. WainwrightAugust 27, 2025 | msn.comThis Is What Whales Are Betting On Summit TherapeuticsAugust 26, 2025 | benzinga.comSummit Therapeutics stock rises after Akeso reports positive trial dataAugust 26, 2025 | za.investing.comSummit Therapeutics PLC $SMMT Holdings Boosted by Russell Investments Group Ltd.August 25, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Sells 24,355 Shares of Summit Therapeutics PLC $SMMTAugust 22, 2025 | marketbeat.comJMP Securities Reiterates Market Outperform Rating for Summit Therapeutics (NASDAQ:SMMT)August 21, 2025 | marketbeat.comAberdeen Group plc Sells 89,615 Shares of Summit Therapeutics PLC $SMMTAugust 20, 2025 | marketbeat.comVanguard Group Inc. Cuts Stock Position in Summit Therapeutics PLC $SMMTAugust 20, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025Diagnosis: Hims & Hers' August Price Dip Is an Opportunity to BuyBy Thomas Hughes | August 6, 2025Ozempic Boom: Hims & Eli Lilly Lead Healthcare BetsBy Gabriel Osorio-Mazilli | August 21, 2025SMMT, SDGR, RXRX, and HIMS Company DescriptionsHims & Hers Health NYSE:HIMS$48.25 +3.79 (+8.52%) Closing price 03:59 PM EasternExtended Trading$48.01 -0.24 (-0.50%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.Recursion Pharmaceuticals NASDAQ:RXRX$4.52 -0.11 (-2.38%) Closing price 04:00 PM EasternExtended Trading$4.54 +0.02 (+0.33%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.Schrodinger NASDAQ:SDGR$18.97 -0.32 (-1.66%) Closing price 04:00 PM EasternExtended Trading$18.93 -0.04 (-0.18%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.Summit Therapeutics NASDAQ:SMMT$23.80 +0.28 (+1.19%) Closing price 04:00 PM EasternExtended Trading$23.78 -0.02 (-0.08%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Insider Selling: Risk Signal or Normal Activity? Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Affirm Crushes Earnings Expectations, Turns Bears into Believers Gold’s Explosive Rally: GDX ETF May Be the Fast Track to Profits Dollar Tree Plunges Into Buy-Zone: A Robust Rebound Is Expected Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
